Skip to main content

Breast Cancer Clinical Trials

Review the breast cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 451-475 of 891

Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy
Status: Enrolling by Invitation
Location: 3 locations
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Status: Enrolling by Invitation
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Non-surgical Approach (Radiation Therapy) for the Treatment of Early Stage Breast Cancer Patients with an Exceptional Response to Neoadjuvant Chemotherapy, NoCUT-BC Trial
Status: Approved
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
A New Molecular Biomarker Test for Adapting Neoadjuvant Treatment in Patients with HER2-Positive Early-Stage Breast Cancer, EUREKA Trial
Status: Approved
Location: 9 locations
Taletrectinib for the Treatment of Patients with CDH1-Mutated, Metastatic Invasive Lobular Breast Cancer, TaCe-1 Trial
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Trastuzumab Deruxtecan and Lovastatin for the Treatment of HER2 Low and Ultralow Advanced, Unresectable or Metastatic Breast Cancer
Status: Approved
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Genetically Engineered Cells (TRICK-NK Cells) for the Treatment of Metastatic or Unresectable and Refractory Breast Cancer
Status: Approved
Location: UT MD Anderson Cancer Center, Houston, Texas
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Status: Temporarily Closed to Accrual
Location: UT MD Anderson Cancer Center, Houston, Texas
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status: Temporarily Closed to Accrual
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Avelumab or Hydroxychloroquine with or without Palbociclib for the Treatment of Stage II-III Breast Cancer, PALAVY Study
Status: Temporarily Closed to Accrual
Location: 6 locations
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in Patients with Breast Cancer
Status: Temporarily Closed to Accrual
Location: 4 locations
Pembrolizumab in Treating Patients with Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
Status: Temporarily Closed to Accrual
Location: UT MD Anderson Cancer Center, Houston, Texas
Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases
Status: Temporarily Closed to Accrual
Location: 3 locations
Pembrolizumab in Treating Patients with Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
Status: Temporarily Closed to Accrual
Location: UT MD Anderson Cancer Center, Houston, Texas
Brain-Directed Stereotactic Radiation Therapy with or without AGulX Gadolinium-Based Nanoparticles for the Treatment of Brain Metastases
Status: Temporarily Closed to Accrual
Location: 2 locations
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Onvansertib in Combination with Paclitaxel for the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: 3 locations
PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss
Status: Temporarily Closed to Accrual
Location: UT MD Anderson Cancer Center, Houston, Texas
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
A Vaccine (MV-s-NAP) for the Treatment of Patients with Invasive Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: Mayo Clinic in Rochester, Rochester, Minnesota
A Vaccine (H2NVAC) before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Status: Temporarily Closed to Accrual
Location: 2 locations
mRNA-2752 with or without a PD1 Inhibitor in Treating Patients with High Grade Ductal Breast Carcinoma In Situ
Status: Temporarily Closed to Accrual
Location: 2 locations
A Combined Vaccine (MVF-HER-2 [597-626] and MVF-HER-2 [266-296]) for the Treatment of Metastatic or Unresectable Breast or Gastrointestinal Cancer
Status: Temporarily Closed to Accrual
Location: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: 9 locations
Chimeric HER2 B-cell Peptide Vaccine Emulsified in Montanide ISA 720 for the Treatment of High-Risk HER2 Positive Breast Cancer
Status: Temporarily Closed to Accrual
Location: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana